L-艾杜糖醛酸钠 | 2073-35-0

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: L-艾杜糖醛酸钠
• 中文别名: L-艾杜糖醛酸
• 英文名称: L-Iduronsaeure
• 英文别名: (2R,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
• CAS: 2073-35-0
• 化学式: C₆H₁₀O₇
• 分子量: 194.141
• InChiKey: IAJILQKETJEXLJ-SKNVOMKLSA-N

物化性质

• 熔点：
  131-132 °C(Solv: methanol (67-56-1))
• 沸点：
  553.4±50.0 °C(Predicted)
• 密度：
  1.748±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于甲醇（轻微加热）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

安全信息

• 储存条件：
  存储条件：2-8°C，密封保存，并确保干燥。

反应信息

• 作为反应物：
  描述：

  zinc(II) nitrate hexahydrate 、 L-艾杜糖醛酸钠 、 [2-[[Methyl-[[4-(1,10-phenanthrolin-2-yl)phenyl]methyl]amino]methyl]phenyl]boronic acid 以 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Fluorescent sensing of uronic acids based on a cooperative action of boronic acid and metal chelate

  摘要：

  设计了一种新的荧光分子传感器，用于尿酸，其特点是采用了硼酸-二醇复合物的双重相互作用和锌(II)-羧酸盐的配位作用。

  DOI：

  10.1039/a703471g
• 作为产物：
  描述：

  1,2-O-isopropylidene-α-D-glucofuranurono-6,3-lactone 在 acidic cationen-exchanger 、 水 作用下， 生成 L-艾杜糖醛酸钠
  参考文献：
  名称：

  Synthesis¹ of L-Iduronic Acid and an Improved Production¹ of D-Glucose-6-C¹⁴

  摘要：

  DOI：

  10.1021/ja01614a072

文献信息

• COMPLEXES OF DERMATAN SULFATE AND DRUGS, GIVING IMPROVED PHARMACOKINETICS
  申请人：Access Pharmaceuticals, Inc.

  公开号：EP0794796A1

  公开（公告）日：1997-09-17
• COMPOSITIONS AND METHODS FOR PRODUCING CHEMICALS AND DERIVATIVES THEREOF
  申请人：Synthetic Genomics, Inc.

  公开号：US20140206047A1

  公开（公告）日：2014-07-24

  The present invention provides methods for producing a product of one or more enzymatic pathways. The pathways used in the methods of the invention involve one or more conversion steps such as, for example, an enzymatic conversion of guluronic acid into D-glucarate (Step 7); an enzymatic conversion of 5-ketogluconate (5-KGA) into L-Iduronic acid (Step 15); an enzymatic conversion of L-Iduronic acid into Idaric acid Step 7b); and an enzymatic conversion of 5-ketocluconate into 4,6-dihydroxy 2,5-diketo hexanoate (2,5-DDH) (Step 16). In some embodiments the methods of the invention produce 2,5-furandicarboxylic acid (FDCA) as a product. The methods include both enzymatic and chemical conversions as steps. Various pathways are also provided for converting glucose into 5-dehdyro-4-deoxy-glucarate (DDG), and for converting glucose into 2,5-furandicarboxylic acid (FDCA). The methods also involve the use of engineered enzymes that perform reactions with high specificity and efficiency. Additional products that can be produce include metabolic products such as, but not limited to, guluronic acid, L-iduronic acid, idaric acid, glucaric acid. Any of the products can be produced using glucose as a substrate or using any intermediate in any of the methods or pathways of the invention.
• US9528133B2
  申请人：——

  公开号：US9528133B2

  公开（公告）日：2016-12-27
• [EN] COMPLEXES OF DERMATAN SULFATE AND DRUGS, GIVING IMPROVED PHARMACOKINETICS<br/>[FR] COMPLEXES DE SULFATE DE DERMATAN ET DE MEDICAMENTS, AMELIORANT LA PHARMACOCINETIQUE
  申请人：ACCESS PHARMACEUTICALS, INC.

  公开号：WO1996019242A1

  公开（公告）日：1996-06-27

  (EN) A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an antitumor drug and may be taxol, a peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9 % (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induced the following $i(in vivo) effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (intestitium); and 4) improvement of the efficiency with which the drug migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.(FR) Compositions supports de médicaments consistant en un médicament complexé à un sulfate de dermatan. Le médicament est de préférence un antitumoral tel que le taxol, un peptide oncoagent ou la vincristine, ou mieux, la doxorubicine. Le sulfate de dermatan, pratiquement pur, contient jusqu'à 9 % en poids de soufre et présente une sursulfatation sélective par les oligosaccharides. Ces compositions qui s'administrent de manière à accéder facilement au système vasculaire y induisent $i(in vivo) les effets suivants: (1) enveloppement endothélial rapide, partiel ou total du support (diagnostique) du médicament; (2) emprisonnement du support, et protection de l'agent captif vis-à-vis de la clairance sanguine vasculaire anticipée (2 minutes) alors que la cavité endothéliale enveloppant le support s'invagine encore dans le compartiment vasculaire; (3) accélération du transport du support dans et/ou à travers les structures vasculaires endothéliales ou sous-endothéliales en direction du compartiment tissulaire (intersticium); et (4) amélioration de l'efficacité de migration du médicament à travers l'endothélium ou les barrières épi-endothéliales ou sous-endothéliales permettant de diminuer la dose nécessaire pour obtenir les effets désirée, par rapport à l'utilisation d'agents usuels. L'absorption par des tissus analogues et la migration trans-épithéliale dans les poumons, la vessie ou les intestins sont également décrits.
• Fluorescent sensing of uronic acids based on a cooperative action of boronic acid and metal chelate
  作者：Masayuki Takeuchi、Masashi Yamamoto、Seiji Shinkai

  DOI：10.1039/a703471g

  日期：——

  A new fluorescent molecular sensor for uronic acids is designed, which features two-point interactions of boronic acid–diol complexation and zinc(II)–carboxylate coordination.

  设计了一种新的荧光分子传感器，用于尿酸，其特点是采用了硼酸-二醇复合物的双重相互作用和锌(II)-羧酸盐的配位作用。